Rallybio’s Recent Trade Activity: A Snapshot

During the 24‑hour window ending at 04:23 AM Central Europe on Thursday, 22 October 2026, Rallybio (ticker RLYB) experienced a modest uptick, rising 0.18 %. At the close of that trading period, one share was priced at USD 16.22 on major exchanges. The company’s circulating supply stands at 5.3 million shares, which, when combined with the current price, translates to a market capitalization of USD 86.8 million. Over the last 24 hours, a total of approximately USD 1.7 million worth of Rallybio shares changed hands.

The stock’s performance relative to the prior month shows a slight decline of 3.25 %, indicating a modest correction after a period of upward momentum. The 200‑day simple moving average (SMA) is USD 12.51, a figure that suggests the stock has been trading above its long‑term trend line in recent sessions. The 52‑week high, reached on June 1, 2026, peaked at USD 17.57, while the 52‑week low, recorded on February 17, 2026, fell to USD 3.67. These historical extremes provide context for the current price level and the range within which the stock has oscillated over the past year.

Comparative Performance of Peer Stocks

The performance of a selection of peers in the same 24‑hour window illustrates how Rallybio’s movement fits within a broader sectoral context:

  • Unifi (UFI): Down 2.33 %, now trading at USD 5.51. Market cap: USD 103.9 million.
  • Elite Express (ETS): Down 0.96 %, now trading at USD 2.16. Market cap: USD 101.3 million.
  • Pine Tree Acquisition (PAXGU): Flat, trading at USD 9.99. Market cap: USD 101.3 million.
  • Inovio (INO): Up 1 %, trading at USD 0.80. Market cap: USD 103.4 million.
  • Black Diamond Therapeutics I (BDTX): Up 14.36 %, trading at USD 2.08. Market cap: USD 104 million.

These figures highlight that while Rallybio’s price change was modest, some peers—most notably Black Diamond Therapeutics I—exhibited a significant rally. Conversely, several stocks experienced declines, suggesting sector‑wide volatility.

Company Overview

Rallybio Corporation operates as a clinical‑stage biotechnology firm focused on the discovery, development, manufacture, and supply of therapies aimed at improving the lives of patients in the United States suffering from severe and rare diseases. The company’s pipeline and strategic initiatives are aimed at addressing unmet medical needs, positioning Rallybio as a potential contributor to advancements in personalized medicine and targeted therapeutics.

By examining Rallybio’s recent trade metrics, its market capitalisation trajectory, and the relative performance of peer companies, investors can gauge the company’s standing within the biotechnology sector and assess its short‑term trading dynamics.